Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Animal Health, Inc. (Jaguar Health) on May 16, 2017. The report addresses a notice received from The NASDAQ Stock Market LLC regarding the Company's failure to meet the minimum bid price requirement for continued listing.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, or margin data for the current period. However, it notes that the Company currently does not have stockholders' equity of at least $5 million, which is a requirement for certain listing extensions. The Company's stock has closed below the minimum $1.00 per share requirement for the last 30 consecutive business days.
Material Changes and Listing Status
- Delisting Notice: On May 16, 2017, NASDAQ notified the Company that its common stock failed to meet the $1.00 minimum bid price standard under Listing Rule 5550(a)(2).
- Grace Period: The Company was granted a 180-calendar-day grace period, ending November 13, 2017, to regain compliance.
- Compliance Requirement: To maintain listing, the Company must evidence a closing bid price of at least $1.00 per share for a minimum of 10 consecutive business days during the grace period.
- Previous Hearing: On April 20, 2017, the NASDAQ Hearings Panel granted continued listing subject to the completion of a proposed merger with Napo Pharmaceuticals, Inc. by July 31, 2017, and meeting a $2.5 million stockholders' equity requirement.
Outlook, Risks, and Contingencies
The Company is working to evidence compliance with NASDAQ requirements, but there is no assurance that it will regain compliance or receive further extensions. If the Company fails to meet the $1.00 bid price requirement by November 13, 2017, eligibility for a second grace period will depend on meeting other initial listing standards, including market value of publicly held shares. As of the filing date, the Company does not meet the $5 million stockholders' equity threshold required for an extension based on current metrics. The filing contains forward-looking statements regarding the proposed merger with Napo Pharmaceuticals and the ability to regain listing compliance, which are subject to significant risks and uncertainties.
Investor Verification Checklist
- Verify the current status of the proposed merger with Napo Pharmaceuticals, Inc. and whether it is on track to close by July 31, 2017.
- Monitor the daily closing bid price of Jaguar Health common stock to ensure it reaches $1.00 for 10 consecutive business days before November 13, 2017.
- Review the Company's stockholders' equity position to determine if it meets the $2.5 million requirement post-merger or the $5 million requirement for alternative extensions.
- Check for any subsequent filings regarding the outcome of the NASDAQ Hearings Panel or further communications from the Listing Qualifications Staff.